Document Detail

Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate.
MedLine Citation:
PMID:  20582546     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Therapeutic strategies on treatment of T1G3 urothelial cancer of the urinary bladder are controversial. The objective of this study was to investigate the impact of photodynamic diagnosis (PDD) on the recurrence-free survival rate of patients with the initial diagnosis of T1G3 bladder cancer. PATIENTS AND METHODS: Between 1995 and 2007, 153 patients were treated for T1G3 bladder cancer at our institution. In 77 patients, initial TUR-BT was performed under PDD condition at our hospital, and 76 patients underwent TUR-BT in a standard white light setting at other institutions. PDD was performed either using 5-aminolevulinate or hexaminolevulinate for induction of fluorescence. Average follow-up was 53.9 months. Fisher's exact test and Kaplan-Meier method were used to test data for significance. RESULTS: Of the 77 patients who were treated using PDD at initial TUR-BT, recurrence was observed in 23 (29.9%) cases, whereas 43 of 76 (56.6%) patients treated without PDD showed recurrence (P < 0.001). The detection rate of additional carcinoma in situ was 35.4% in the PDD group versus 21.8% in the white light group (P = 0.077). A limitation of the present study is the retrospective, monocentre setting, which is more likely to be biased. CONCLUSION: PDD during initial TUR-BT in T1G3 bladder cancer seems to reduce significantly the rate of recurrence in our study population. Therefore, PDD seems to be associated with superior initial tumour control and more effective tumour treatment even in patients with highly aggressive tumours like T1G3 bladder cancer.
Peter Stanislaus; Dirk Zaak; Thomas Stadler; Stefan Tritschler; Ruth Knüchel; Christian G Stief; Alexander Karl
Related Documents :
10736496 - Urinary tissue polypeptide-specific antigen for the diagnosis of bladder cancer.
22229096 - Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.
19711266 - Palliative treatment of intractable hematuria in context of advanced bladder cancer: a ...
2147716 - Palmar keratoses in family members of individuals with bladder cancer.
16020976 - Leptin is associated with an increased female colorectal cancer risk: a nested case-con...
11192946 - Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer.
Publication Detail:
Type:  Journal Article     Date:  2010-06-26
Journal Detail:
Title:  World journal of urology     Volume:  28     ISSN:  1433-8726     ISO Abbreviation:  World J Urol     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-23     Completed Date:  2010-11-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8307716     Medline TA:  World J Urol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  407-11     Citation Subset:  IM    
Department of Urology, Ludwig-Maximilians-University, LMU, Marchionistr. 15, 81377, Munich, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aminolevulinic Acid / analogs & derivatives,  diagnostic use
Carcinoma in Situ / diagnosis*,  epidemiology
Cystoscopy / methods*,  statistics & numerical data
Follow-Up Studies
Kaplan-Meiers Estimate
Middle Aged
Neoplasm Recurrence, Local / diagnosis*,  epidemiology
Photosensitizing Agents / diagnostic use
Retrospective Studies
Urinary Bladder Neoplasms / diagnosis*,  epidemiology,  surgery
Reg. No./Substance:
0/5-aminolevulinic acid hexyl ester; 0/Photosensitizing Agents; 106-60-5/Aminolevulinic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Multidetector computed tomography with triple-bolus contrast medium administration protocol for preo...
Next Document:  Prospective study of sexual dysfunction in men with rectal cancer: feasibility and results of nerve ...